Blue Goose Capital
Overview
Blue Goose Capital is a venture capital firm investing in early-stage biotech and pharmaceutical companies in the US and Spain. The firm focuses on companies with outstanding technology and strong intellectual property, aiming to support the growth and development of innovative healthcare solutions. Blue Goose Capital has invested in AtG Therapeutics, a Barcelona-based company developing precision medicine therapies for advanced cancers, and has announced plans to invest in biotech companies in the US starting from Series A rounds in March 2024.
Investment Focus
- Outstanding technology
- Strong intellectual property
- Early-stage biotech and pharmaceutical focus
Portfolio Companies
Reach Blue Goose Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Blue Goose Capital
What sectors does Blue Goose Capital invest in?
Blue Goose Capital invests in Pharmaceuticals, Medical Devices, Biotechnology and Data, and is based in Cambridge, United States. Blue Goose Capital is listed as a venture capital in the ConnectSafely investor database.
What stage does Blue Goose Capital invest at?
Blue Goose Capital backs companies at Seed, Early Stage, Series A and Series B.
Which regions does Blue Goose Capital invest in?
Blue Goose Capital invests across United States and Spain.
Who are the partners at Blue Goose Capital?
Team members listed for Blue Goose Capital include Doug Zingale (Managing Partner).
What companies has Blue Goose Capital invested in?
Blue Goose Capital's portfolio includes AtG Therapeutics.
How do I contact Blue Goose Capital?
Blue Goose Capital's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
